title: A phase II study of the combination of carboplatin and ifosfamide in previously untreated metastatic small cell lung carcinoma.
abstract: This Phase II study evaluated the combination of two active agents in small cell lung carcinoma (SCLC): carboplatin and ifosfamide. Thirty previously untreated patients (27 men and 3 women) with a median age of 59 years were included in this study. Twelve patients had one metastatic site and 18 had two or more metastatic sites. The median performance status was 80%. The chemotherapy (CT) regimen administered during the course of this study consisted of carboplatin (300 mg/m2) and ifosfamide (4 g/m2) plus mesna every 4 weeks. All 30 patients were evaluable: 1 achieved a complete remission (CR) and 18 achieved a partial remission (PR) (objective response rate, 63%). The median response time was 3 months and the median survival time was 8 months (range, 1 to 25+ months). Bone marrow toxicity was Grade III in three patients and Grade IV in four patients. The carboplatin and ifosfamide combination was well tolerated. No cross-resistance with the doxorubicin and etoposide regimen was established because 4 of 11 patients responded to this combination (+/- cisplatin) after failing to respond to the ifosfamide and carboplatin regimen. The ifosfamide and carboplatin combination may be considered for inclusion in non-cross-resistant alternating CT schedules.
authors.affiliation: Department of Medicine, Institut Gustave Roussy, Villejuif.
authors.forename: T
authors.initials: T
authors.lastname: Le Chevalier
authors.forename: F
authors.initials: F
authors.lastname: Thomas
authors.forename: R
authors.initials: R
authors.lastname: Subirana
authors.forename: P
authors.initials: P
authors.lastname: Baldeyrou
authors.forename: P
authors.initials: P
authors.lastname: Ruffie
authors.forename: R
authors.initials: R
authors.lastname: Arriagada
authors.forename: M
authors.initials: M
authors.lastname: Chazard
authors.forename: T
authors.initials: T
authors.lastname: Tursz
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D016190:Carboplatin / Q000008:administration & dosage* / Q000009:adverse effects; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000556:secondary*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage* / Q000009:adverse effects; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D015996:Survival Rate
chemical_list: D016190:Carboplatin; D007069:Ifosfamide